Trial Profile
Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Liothyronine (Primary)
- Indications Hypothyroidism
- Focus Pharmacodynamics
- Sponsors IPE
- 01 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2014 New trial record